X4 Pharmaceuticals, Inc. ( XFOR) Stock. Should you Buy or Sell? $ 1.18
0.01 (0.84 %)
X4 Pharmaceuticals, Inc. Analysis
Updated on 10-09-2022| Symbol | XFOR |
| Price | $1.18 |
| Beta | 0.666 |
| Volume Avg. | $328.3 thousand |
| Market Cap | $81 M |
| 52 Week Range | $0.861 - $6.18 |
X4 Pharmaceuticals, Inc. opened the day at $1.18 which is +'0.84 % on yesterday's close. X4 Pharmaceuticals, Inc. has a 52 week high of $6.18 and 52 week low of $0.861, which is a difference of $5.319. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $81 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy X4 Pharmaceuticals, Inc. for $81 M, it would take 15 years to get your money back. X4 Pharmaceuticals, Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
X4 Pharmaceuticals, Inc. Stock Forecast - Is X4 Pharmaceuticals, Inc. a Buy or Sell?
| DCF Score | Strong Buy | |
| ROE Score | Strong Sell | |
| ROA Score | Sell | |
| DE Score | Buy | |
| PE Score | Sell | |
| PB Score | Strong Buy | |
| Overall Recommendation | Neutral |
Growth and Value
| PE Ratio | -0.447 |
| Dividend Yiel | 0.000 |
| Net Profit Margin | 0.000 |
Valuing X4 Pharmaceuticals, Inc.
| Price Book Value Ratio | 1.390 | Price To Book Ratio | 1.390 |
| Price To Sales Ratio | 0.000 | Price Earnings Ratio | -0.447 |
How liquid is X4 Pharmaceuticals, Inc.
| Current Ratio | 2.390 |
| Quick Ratio | 2.153 |
Debt
| Debt Ratio | 0.629 | Debt Equity Ratio | 1.694 |
| Long Term Debt To Capitalization | 0.488 | Total Debt To Capitalization | 0.561 |
Latest news about X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals (XFOR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR ) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants Dan Ferry - LifeSci Advisors, IR Dr. Paula Ragan - Chief Executive Officer Adam Mostafa - Chief Financial Officer Art Taveras - Chief Scientific Officer Diego Cadavid - Chief Medical Officer Mary DiBiase - Chief Operating Officer Conference Call Participants Stephen Willey - Stifel Eva Privitera - Cowen Mayank Mamtani - B. Riley Securities Arthur He - H.C.
BOSTON, July 26, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients with diseases of the immune system, today announced that it will report its financial results for the second quarter ended June 30, 2022, and provide an update on recent business highlights, on August 4, 2022.
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Verve Therapeutics, Vertex Join Forces For Liver Disease-Focused Gene Program Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Verve Therapeutics Inc (NASDAQ: VERV) announced.
BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with rare immune system disorders, today announced that it will present research data supporting the mechanism and market potential of its lead drug candidate, mavorixafor, as part of three posters at the upcoming European Hematology Association (EHA) congress to be held in Vienna, Austria, June 9-17, 2022.
About X4 Pharmaceuticals, Inc.
Description :
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.
